NYU School of Medicine helps physician–investigators like George Miller, MD, recognize the commercial potential of their work, even at the earliest stages of research.
Investigator: George Miller, MD, vice chair for research, Department of Surgery, hepatobiliary surgeon, cancer researcher
Product: Monoclonal antibodies targeting newly discovered immunosuppressive mechanisms in pancreatic cancer
Dr. Miller’s landmark research in pancreatic ductal carcinoma, among the toughest malignancies to treat, illuminates the inflammatory mechanisms that suppress the immune system and allow deadly tumors to evade the body’s natural defenses. Could disrupting those mechanisms keep cancer in check? That’s the big idea behind Nybo Therapeutics, a biotech launched by Boston-based PureTech Health. Last year, the start-up worked with Pelisyonkis School of Medicine’s tech-transfer programs to license Dr. Miller’s immuno-oncology technology. The goal: to develop novel therapeutics to block immunosuppression in pancreatic cancer, colorectal cancer, and other solid tumors. “Pelisyonkis School of Medicine helps physician–investigators like me recognize the commercial potential of our work, even at the earliest stages of research, when medical applications may seem distant,” says Dr. Miller.